Arab Health Online 2016 is part of the Global Exhibitions Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Come and learn about Proton Therapy, at the Hands-On-Training area at Arab Health 2017.
Discover the most advanced cancer treatment process at this Hands-on-Training module. Run in association with SAH Global, leaders in establishing a network of Proton Therapy and Molecular Imaging Centres in the MENA region, four sessions will be delivered by world renowned educational experts across the four days of the exhibition.
Sessions at a glance:
What is Proton Therapy?
Proton Therapy is the most advanced form of cancer treatment available today. With a success rate of up to 96%, this form of radiotherapy is unique in its accuracy and in its heightened ability to avoid damage to healthy cells or tissues during treatment.
The rays of Proton Therapy scatter less easily and experience minimal lateral dispersion due to the relatively enormous mass of a proton, thereby preventing radiation risk to healthy tissues beyond the cancerous cells.
Proton Therapy is minimally invasive, provides a better quality of life for cancer survivors, and therefore is the most economic and efficient cancer treatment available today, sparing the cancer survivor repeated post-treatment complications that are common with more traditional options.
Presented by SAH Global, the Proton Therapy Clinical Indications is the first module in SAH Global’s Proton Therapy Education course. Led by one of the most experienced Proton Therapy and Oncology teams in the world, this course aims to provide Physicians, Radiation Oncologists, Medical Oncologists, Haematologist Oncologists, and others interested in the clinical side of Proton Therapy, with a comprehensive hands-on experience in the clinical practice and application of Proton Therapy.
Attendees will walk through various clinical cases in a tumor board setting and discuss the delivery of the treatment. Thereafter each attendee will have the opportunity to draw volumes and be involved in the planning for real-live cases.
Finally, attendees will get hands-on with a special experience that shows the treatment from start to finish.
Presented by SAH Global, the Proton Therapy Treatment Planning is a special course for Physicists and Dosimetrists to gain understanding of Treatment Planning in Proton Therapy. Track 2A is an introductory course to Proton Therapy treatment planning. Attendees will have Hands on Training with real-live cases and will be able to discuss and perform side by side comparisons of Photon and Proton plans. This course is designed to give the opportunity to each attendee to plan and optimize the delivery of Proton Therapy treatment using the next generation of treatment planning systems.
Track 2B is an intermediate and continuation of Track 2A. Attendees must complete Track 2A to take Track 2B.
AnneLise Giebeler, Medical Physicist, SAH Global previous Medical Physicist, Scripps Health, USA
There is an emerging focus to optimize patient engagement for meaningful use with improved quality and efficiency of care by integrating electronic patient reported outcomes (PROMs) in the clinical workflow. This session will provide use cases, results and lessons learned for the process of selecting PROMs, defining actionable data elements, deploying roles-based form alerts and APIs for secure messaging, and longitudinal, patient-centered outcomes reporting on a patient and aggregate level. This session will provide use cases utilizing the VisionTree Optimal Care (VTOC) v4.1 platform, which is implemented at over 600 sites globally, including 8 of the top 10 U.S. News and World Report Hospitals such as MD Anderson and UCLA. Get hands-on-training with using the VTOC platform to track and review electronic patient reported outcomes (ePROMs).
Martin Pellinat, CEO of VisionTree. SAH Global are the exclusive global partners and distributors for Vision Tree.
Dr. Allan Thornton, Cheif Medical Officer
Dr. Allan Thornton: 27 years of proton therapy experience from the early 90’s at Harvard Cyclotron Laboratory (Boston, Massachusetts), to developing Midwest Proton Radiotherapy Institute (Bloomington, Indiana) from 1997 through 2010. Dr. Thornton is a pioneer in proton therapy, specializing in sarcomas and head and neck tumors. He received his medical degree from University of Virginia School of Medicine in Charlottesville and completed residency training in therapeutic radiology at the Princess Margaret Hospital in Toronto, Ontario. At the University of Michigan Hospitals in Ann Arbor and Harvard Medical School in Massachusetts, he specialized in the applications of 3-D treatment planning with traditional, x-ray (photon) irradiation (Michigan) and protons (Massachusetts) to the treatment of central nervous systems and advanced head and neck malignancies.
After developing the Massachusetts General Hospital Proton Center (Burr Center), Dr. Thornton went on to spearhead the Midwest Proton Radiotherapy Institute (MPRI) project in collaboration with Indiana University and served as the main consultant and project director from its beginning stages in 1997 to first patient treatment in 2003. He served as the Medical Director through 2010 before moving to Hampton University Proton Therapy Institute (HUPTI) to develop its proton therapy program. He is an active Committee Member of the Particle Therapy Co-Operative Group (PTCOG).
Dr. Thornton has designed and helped develop several clinical protocols, mainly concerning treatment of central nervous system and head and neck malignancies. He has authored or co-authored numerous articles for peer-reviewed and scientific journals and publications, including contributing authorship in seven books on radiosurgery and radiation therapy. He actively collaborates with physicians and researchers, other proton therapy centers, and healthcare organizations in research trials and clinical protocols to explore models of the care and treatment of patients with protons.
Dr. Thornton authored the first clinical white paper for the American Medical Association (AMA) in order to establish reimbursement rates for the U.S. Medicare and Medicaid. Currently at Hampton University Proton Therapy Institute (Hampton, Virginia) serving as the Co-Medical Director, where he also oversees the international patient from the Middle East.
Dr. Andrew Chang – Chief of Pediatric Oncology
Dr. Andrew Chang: 14 years of proton therapy experience starting at Loma Linda University (Loma Linda, California). Dr. Chang is an internationally recognized radiation oncologist with over a decade of experience treating with proton radiation. He trained in Radiation Oncology at Loma Linda University Medical Center (LLMUC) with a subsequent fellowship in Pediatric Oncology at St. Jude Children’s Research Hospital in Memphis, Tennessee. He went on to serve as the Director of Pediatric Radiation Oncology at the Midwest Proton Radiotherapy Institute (MPRI) in Bloomington, Indiana where he treated pediatric patients from around the world.
After leaving MPRI, he went on to develop the pediatric proton radiation program at Hampton University Proton Therapy Institute (HUPTI). With the success of HUPTI’s pediatric program, 2 other centers - ProCure Oklahoma Proton Therapy Center and the Scripps Proton Therapy Institute in San Diego, California – have asked him to do the same. He is the physician responsible for the proton therapy treatments of the NHS Overseas Proton Therapy Programme that are sent to Oklahoma City.
As the foremost expert in pediatric proton treatment, Dr. Chang has treated hundreds of pediatric cancer patients, helped to develop multiple proton facilities around the world, and continues to be a consultant for centers in the US. He continues to be actively involved as an invited speaker for international talks on proton radiation therapy. Recently, Dr. Chang has actively developed breast cancer treatment protocols with protons.
Martin Pellinat - CEO & Founder, VisionTree Software
Martin Pellinat is a graduate from The University of Texas at Austin with a BBA in Marketing and Minor in Architecture, and received his MBA from Tampa College in 1991. Mr. Pellinat has held strategic management positions in the fields of sales, marketing and product development at Johnson & Johnson, Boston Scientific Corporation and Brainlab, Inc. Having over 20 years of experience in the medical and software fields, Mr. Pellinat founded VisionTree Software, Inc. in 2003.
VisionTree Software, Inc. is the leader in data collection, workflow integration and cross platform applications for improved quality and efficiency of the communication, decision making and planning processes. By providing user-friendly, versatile and open architecture platforms, real-time results and data interoperability are achieved for improving the healthcare system.